Ftse Mib
33.305,46
-1,34%
DAX
19.060,31
-0,60%
S&P 500
5.916,98
0,40%
NASDAQ
18.987,47
1,04%
Bitcoin
91.832,16
1,41%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Nektar Therapeutics (NKTR) Nektar Therapeutics (NKTR) Notizie

Nektar Therapeutics

NKTR
1,03
0,00 (0,00%)
Dopo l'orario di negoziazione
Ultimo aggiornamento: 22:15:30
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
19/11/202422:10EDGAR2Form 144 - Report of proposed sale of securities
19/11/202421:28EDGAR2Form 144 - Report of proposed sale of securities
19/11/202421:17EDGAR2Form 144 - Report of proposed sale of securities
18/11/202421:30PRNUSNektar Therapeutics Presents First Preclinical Data from..
14/11/202418:17EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
14/11/202415:18EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
08/11/202423:31EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
07/11/202422:31EDGAR2Form 8-K - Current report
07/11/202422:15PRNUSNektar Therapeutics Reports Third Quarter 2024 Financial..
07/11/202416:15PRNUSNektar and Collaborators Present Late-breaking Results from..
07/11/202400:00PRNUSNektar Therapeutics to Participate in Upcoming Investor..
04/11/202414:52EDGAR2Form 8-K - Current report
04/11/202414:30PRNUSNektar Announces Definitive Agreement with Ampersand Capital..
31/10/202423:00PRNUSNektar to Announce Financial Results for the Third Quarter..
29/10/202414:00PRNUSNektar Announces Publication in Nature Communications of..
17/10/202418:07PRNUSNektar Announces Publication in Blood of Phase 1 Data for..
25/9/202409:30PRNUSNektar Therapeutics Announces Multiple Presentations for..
03/9/202415:00PRNUSNektar Management to Present at Upcoming Investor..
21/8/202403:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/8/202403:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/8/202403:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/8/202422:13EDGAR2Form 144 - Report of proposed sale of securities
19/8/202422:03EDGAR2Form 144 - Report of proposed sale of securities
19/8/202421:45EDGAR2Form 144 - Report of proposed sale of securities
08/8/202422:20EDGAR2Form 8-K - Current report
08/8/202422:15PRNUSNektar Therapeutics Reports Second Quarter 2024 Financial..
02/8/202400:00PRNUSNektar to Announce Financial Results for the Second Quarter..
15/6/202400:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202422:11EDGAR2Form 144 - Report of proposed sale of securities
12/6/202415:30PRNUSNektar Therapeutics Presents First Preclinical Data on..
06/6/202422:05EDGAR2Form 8-K - Current report
06/6/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
05/6/202423:30EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
31/5/202400:00PRNUSNektar Management to Present at Upcoming Investor..
28/5/202422:51EDGAR2Form S-3 - Registration statement under Securities Act of..
21/5/202403:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202403:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202403:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202422:25EDGAR2Form 144 - Report of proposed sale of securities
17/5/202422:22EDGAR2Form 144 - Report of proposed sale of securities
17/5/202422:14EDGAR2Form 144 - Report of proposed sale of securities
13/5/202422:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202422:20EDGAR2Form 8-K - Current report
09/5/202422:15PRNUSNektar Therapeutics Reports First Quarter 2024 Financial..
03/5/202400:00PRNUSNektar to Announce Financial Results for the First Quarter..
22/3/202419:00PRNUSNektar Management to Present at the H.C. Wainwright 2nd..
05/3/202423:11EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
05/3/202415:00PRNUSNektar Therapeutics Announces Initiation of Phase 2b..
04/3/202422:20EDGAR2Form 8-K - Current report
04/3/202422:15PRNUSNektar Therapeutics Reports Fourth Quarter and Year-End 2023..
Apertura: 1,02 Min: 1,00 Max: 1,04
Chiusura: 1,03

La tua Cronologia

NASDAQ
NKTR
Nektar Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network